當前位置:深圳遠揚化學技術有限公司>>技術文章>>匹伐他汀申報用全套雜質
匹伐他汀背景及作用機理:
冠心病是威脅人類健康和生命的常見病和多發病,以低密度脂蛋白(LDL)升高為特征的高膽固醇血癥則是誘發冠心病的主要危險因子之一。常用的降血脂藥如煙酸類、樹脂類或貝特類等療效都難盡人意,降脂作用的是被稱為他汀類(statins)的藥物。他汀類藥物共同的作用機制是都屬于3—羥—3—甲基—戊二酰輔酶A(HMG—CoA)還原酶抑制劑,目前在世界廣泛應用的主要有6種:洛伐他汀(lovastatin),普伐他汀(pravastatin),辛伐他汀(simvastatin),西立伐他汀(cerivastatin),氟伐他汀(fluvastatin)和阿托伐他汀(atorvastatin)。而近期由Kowa公司開發的新型他汀類藥物匹他伐他汀鈣,因其良好的降膽固醇作用而被稱為“超級他汀類藥物”(Superstatin)。
深圳遠揚化學技術有限公司可提供匹伐他汀申報所用全套雜質, 隨貨附CoA證書,HNMR,MS,HPLC圖譜,純度符合申報要求,匹伐他汀雜質為我司優勢雜質,長期備有庫存,發貨快。如需匹伐他汀鈣雜質相關詳細信息,歡迎我司業務人員(何:phastandards Q.Q:781007885)獲取~
除自主品牌雜質對照品外,我司還代理英國NIBSC標準品,美國劍橋CIL同位素標準品,美國NIST標準物質,歐洲標準局IRMM標準物質,加拿大TRC標準品,TLC標準品,MOLCAN標準品,NRC標準品等,歡迎洽談。
附:匹伐他汀申報用全套雜質列表:
Pitavastatin | (+)-Monocalcium bis{(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoate} |
Pitavastatin Impurity 1 | (3R,6E)-7-[2-cyclopropyl-4-(4-flurophenyl)-3-quinolinyl]-3-hydroxy-5-oxo-6-heptenoate |
Pitavastatin Impurity 2 | (3S,5R,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid calcium salt |
Pitavastatin Impurity 3 | (4R,6S,E)-6-[2-[2-Cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl] vinyl] tetrahydro-4-hydroxypyran-2-one |
Pitavastatin Impurity 4 | 7-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-6-heptenoic Acid |
Pitavastatin Impurity 5 | (3R,5R,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid calcium salt |
Pitavastatin Impurity 6 | (3S,5S,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid calcium salt |
Pitavastatin Impurity 7 | (3R,5S,6E)-7-[2-Cyclopropyl-4-phenyl-quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid calcium salt |
Pitavastatin Impurity 8 | [[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]methyl]triphenyl-phosphonium Bromide |
Pitavastatin Impurity 9 | (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl]-2,2-dimethyl-1,3-dioxane-6-heptenoic acid t-butyl ester |
Pitavastatin Impurity 10 | (3R,5S,E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxy-N-(1-phenylethyl)hept-6-enamide |
Pitavastatin Impurity 11 | Sodium (5S, 6E)-7-[2-cyclopropyl-4-(4-flurophenyl)-3-quinolinyl]-5-hydroxy-3-oxo-6-heptenoate |
Pitavastatin Impurity 12 | Ethyl (3R, 6E)-7-[2-cyclopropyl-4-(4-flurophenyl)-3- quinolinyl]-3-hydroxy-5-oxo-6-heptenoate |
Pitavastatin Impurity 13 | Ethyl (5S, 6E)-7-[2-cyclopropyl-4-(4-flurophenyl)-3-quinolinyl]-5-hydroxy-3-oxo-6-heptenoate |
Pitavastatin Impurity 14 | (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid methyl ester |
Pitavastatin Impurity 15 | (3R,5S,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid ethyl ester |
Pitavastatin Impurity 16 | (3R,5S)-5-(6-Cyclopropyl-10-fluoro-7,8-dihydrobenzo[k]phenanthridin-8-yl)-3,5-dihydroxypentanoic acid sodium salt |
Pitavastatin Impurity 17 | 2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinemethanol |
Pitavastatin Impurity 18 | (3R,5R,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid ethyl ester |
Pitavastatin Impurity 19 | (3S,5R,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid ethyl ester |
Pitavastatin Impurity 20 | (3S,5S,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid ethyl ester |
Pitavastatin Impurity 21 | (3R,5S,6E)-7-(2-Cyclopropyl-4-phenyl-3-quinolinyl)-3,5-dihydroxy-6-heptenoic Acid tert-Butyl Ester |
Pitavastatin Impurity 22 | 2-((4R,6S)-6-((E)-2-(2-Cyclopropyl-4-phenylquinolin-3-yl)vinyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetic Acid tert-Butyl Ester |
請輸入賬號
請輸入密碼
請輸驗證碼
以上信息由企業自行提供,信息內容的真實性、準確性和合法性由相關企業負責,化工儀器網對此不承擔任何保證責任。
溫馨提示:為規避購買風險,建議您在購買產品前務必確認供應商資質及產品質量。